Get the Stockscreener App
3.95
3.67%
0.14
After Hours:
4.24
0.29
+7.34%
Medicus Pharma Ltd stock is traded at $3.95, with a volume of 38,482.
It is up +3.67% in the last 24 hours and up +38.11% over the past month.
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.
See More
Previous Close:
$3.81
Open:
$4.06
24h Volume:
38,482
Relative Volume:
1.37
Market Cap:
$47.09M
Revenue:
-
Net Income/Loss:
$-11.73M
P/E Ratio:
-2.8569
EPS:
-1.3826
Net Cash Flow:
$-10.37M
1W Performance:
-0.25%
1M Performance:
+38.11%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.7924
$4.06
1-Week Range:
$3.72
$4.3912
52-Week Range:
$1.80
$4.3912
Medicus Pharma Ltd Stock (MDCX) Company Profile
Compare MDCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
3.95 | 47.09M | 0 | -11.73M | -10.37M | -1.3826 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Medicus Pharma Ltd Stock (MDCX) Latest News
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Medicus Pharma’s Phase 2 skin cancer trial hits key milestoneICYMI - Proactive Investors Australia
Medicus Pharma Ltd Poised for Growth: Buy Rating Reaffirmed Amid Promising Developments and Upcoming Catalysts - TipRanks
Medicus Pharma advances Phase 2 clinical study, eyes FDA fast-track approval - Proactive Investors USA
Promising Phase 2 Study and Innovative Approach Boost Confidence in Medicus Pharma Ltd. - TipRanks
Medicus Pharma expects interim data from Phase 2 skin cancer trial shortly - Proactive Investors Australia
Medicus Pharma Advances Phase 2 BCC Clinical Study with FDA Submission Plans - TipRanks
Medicus Pharma announces phase 2 study SKNJCT-003 underway - TipRanks
Medicus Pharma Ltd. Reports Progress in Phase 2 Clinical Study of D-MNA for Basal Cell Carcinoma - Nasdaq
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 - GlobeNewswire
Medicus Pharma Provides Update On SKNJCT-003 Phase 2 Clinical Study -February 14, 2025 at 07:33 am EST - Marketscreener.com
Skin Cancer Breakthrough: Medicus Phase 2 Trial Shows Promise After Phase 1 Success - StockTitan
Medicus Pharma signs standby equity purchase agreement; announces intention to voluntarily delist from TSXV - MSN
Medicus Pharma secures $15 million funding option - MSN
Medicus Pharma announces equity deal, shifts focus to Nasdaq - Proactive Investors Australia
Medicus Pharma enters SEPA, intends to voluntarily delist from TSX - TipRanks
Medicus Pharma Announces Equity Purchase Agreement and TSXV Delisting - TipRanks
Medicus Pharma secures $15 million funding option By Investing.com - Investing.com Nigeria
Medicus (MDCX) Lands Major $15M Financing Deal While Streamlining Exchange Presence - StockTitan
Medicus Pharma Ltd. Enters into Standby Equity Purchase - GlobeNewswire
MDCX Unlocks $15M Capital Pipeline While Streamlining to Single NASDAQ Listing - StockTitan
Quantum Biopharma in Court With Dr. Raza Bokhari on January 24 - WICZ
Merck KGaA (OTCMKTS:MKKGY) and Medicus Pharma (NASDAQ:MDCX) Critical Contrast - Defense World
Medicus Pharma Ltd. Announces Change of Auditor - TipRanks
Medicus Pharma (NASDAQ:MDCX) Upgraded at Brookline Capital Management - Defense World
Brookline starts coverage on Medicus Pharma stock with Buy rating - Investing.com India
Brookline starts coverage on Medicus Pharma stock with Buy rating By Investing.com - Investing.com Nigeria
Medicus Pharma initiated at buy by Brookline Capital - MSN
Cartoning Machines Market Size to Approach USD 13.58 Bn by 2034 - GlobeNewswire Inc.
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors USA
Medicus Pharma CEO charts course for 2025 with clinical milestones for SkinJect - Proactive Investors Australia
Medicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patchICYMI - Proactive financial news
Medicus Pharma achieves key milestone with FDA MUMS designation for cancer treatment in Horses - Proactive financial news
What we think of the 3 big winners of the ASX 100 - Morningstar.com.au
Medicus Pharma’s horse skin cancer treatment wins MUMS designation from FDA - Proactive Investors Australia
Medicus Pharma Eyes Veterinary Market with FDA Designation - TipRanks
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch - The Manila Times
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation - GlobeNewswire
Medicus Pharma Secures FDA MUMS Status for Novel Cancer Treatment Patch in $200M+ Equine Market - StockTitan
Medicus Pharma Ltd. Announces Minor Use Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch - Marketscreener.com
Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI - Proactive Investors Australia
ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer - citybiz
ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer - BioSpace
Medicus Pharma and Swanielle partner to expand BCC drug trial to Asia-Pacific - Yahoo Finance
Medicus Pharma collaborates to expand mid-stage cancer treatment study in Asia-Pacific region - MSN
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activit - GuruFocus.com
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (CVE:MDCX) - Proactive Investors Australia
Medicus Pharma eyes pivotal trial for skin cancer therapy as Phase 2 enrollment progresses - Proactive Investors Australia
Medicus Pharma’s Phase 2 study enrolls 25% of patients and expands into Asia-Pacific Region - Proactive Investors UK
Medicus Pharma partners with Swanielle to expand skin cancer study into Asia-Pacific - Proactive Investors Australia
Medicus Pharma Expands Asia-Pacific Clinical Study - TipRanks
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):